stoxline Quote Chart Rank Option Currency Glossary
  
Helius Medical Technologies, Inc. (HSDT)
0.879  0.003 (0.34%)    07-17 16:00
Open: 0.86
High: 0.879
Volume: 19,048
  
Pre. Close: 0.876
Low: 0.8485
Market Cap: 3(M)
Technical analysis
2024-07-17 5:27:56 PM
Short term     
Mid term     
Targets 6-month :  1.26 1-year :  1.45
Resists First :  1.08 Second :  1.24
Pivot price 0.92
Supports First :  0.81 Second :  0.67
MAs MA(5) :  0.85 MA(20) :  0.94
MA(100) :  3.28 MA(250) :  5.94
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  16.1 D(3) :  11.2
RSI RSI(14): 31.4
52-week High :  13.43 Low :  0.81
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HSDT ] has closed above bottom band by 32.2%. Bollinger Bands are 84.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.88 - 0.88 0.88 - 0.89
Low: 0.84 - 0.84 0.84 - 0.85
Close: 0.87 - 0.88 0.88 - 0.89
Company Description

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Headline News

Fri, 28 Jun 2024
Helius Medical Technologies Enhances Equity Plan and Confirms Directors - TipRanks

Wed, 29 May 2024
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier - GlobeNewswire

Thu, 23 May 2024
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS - Yahoo Finance

Tue, 14 May 2024
Earnings call: Helius Medical eyes FDA approval, CMS reimbursement - Investing.com

Fri, 10 May 2024
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024 - Yahoo Finance

Thu, 09 May 2024
Helius Medical Technologies Awaits CMS Decision on Medicare Reimbursement Rates for Innovative Device - MyChesCo

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.51e+006 (%)
Held by Institutions 0.7 (%)
Shares Short 67 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.175e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 530.3 %
Return on Equity (ttm) -76.1 %
Qtrly Rev. Growth 668000 %
Gross Profit (p.s.) 13.41
Sales Per Share -136.86
EBITDA (p.s.) 0
Qtrly Earnings Growth -13.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.63
Stock Dividends
Dividend 0
Forward Dividend 54760
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android